LYEL
LYEL clinical trials: Lyell Immunopharma, Inc.
Every trial on ClinicalTrials.gov where Lyell Immunopharma, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
LYEL on the catalyst calendar · LYEL registry changes
- Primary completion Dec 2029Sponsor estimatePhase 3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc. · Large B-cell LymphomaRecruitingLYELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 1/Phase 2NCT05319314LYL273 for Patients With Relapsed or Refractory mCRCLyell Immunopharma, Inc. · Colorectal CancerRecruitingLYELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2028Sponsor estimatePhase 1/Phase 2NCT05826535Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaLyell Immunopharma, Inc. · Relapsed Non-Hodgkin LymphomaRecruitingLYELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2025ActualNo phase registeredNCT05891197A Biomarker Screening Protocol for Participants With Solid TumorsLyell Immunopharma, Inc. · Triple Negative Breast CancerTerminatedLYELLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 9, 2025ActualPhase 1NCT05573035A Study to Investigate LYL845 in Adults With Solid TumorsLyell Immunopharma, Inc. · MelanomaTerminatedLYELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2024ActualPhase 1NCT05274451A Study to Investigate LYL797 in Adults With Solid TumorsLyell Immunopharma, Inc. · Triple Negative Breast CancerTerminatedLYELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 9, 2025ActualPhase 1/Phase 2NCT06153095A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)Lyell Immunopharma, Inc. · Systemic Lupus ErythematosusWithdrawnLYELLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner